Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations

DOI: 10.2147/OTT.S161919

Keywords: AML, refractory diseases, relapsed diseases, decitabine, chemotherapy

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text